Carbapenem resistant Enterobacteriaceae – second update

  28 September 2019

Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options. Hypervirulent carbapenem-resistant K. pneumoniae strains have been reported presenting an additional threat with a potential for global dissemination. The spread of high risk clones and plasmids carrying carbapenemases in healthcare settings is a major cause of the spread of CRE in EU/EEA countries. Recent events of cross-border importation after patient transfer and large regional outbreaks as well as the worsening epidemiologic situation of carbapenemase-producing CRE in the EU/EEA highlight the high risk for further spread of CRE and the need for enhanced control efforts.

Source: ECDC
Authors: ECDC
Effective Surveillance  
Back


Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
  • No costs (until year end 2019)

Festive Launch Database 19 Nov Symposium Dinner ‘Emerging Antimicrobials and Diagnostics in AMR 2019
Click to join the Symposium Dinner (to join the Symposium separate registration obligatory)

Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!